<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01687439</url>
  </required_header>
  <id_info>
    <org_study_id>NSCLC0901</org_study_id>
    <nct_id>NCT01687439</nct_id>
  </id_info>
  <brief_title>Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: functional imaging and quantitative imaging detection of the effects of
      Endostar combined with chemotherapy and radiotherapy on Non-small Cell Lung Cancer (NSCLC).

      Secondary objective: To evaluate 1) the role of Endostar in regulating tumor vessels and
      normalizing of microenvironment; 2) Toxicity of Endostar combined with chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor blood volume</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor blood flow</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Permeability-surface area product</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18-FDG PET SUV values</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients receive one cycle of Endostar monotherapy, two cycles of Endostar combined with chemotherapy (vinorelbine plus cisplatin) treatment, followed by Endostar plus radiotherapy treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>7.5mg/m2, D1-14</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>25-30mg/m2, D1,8</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m2, D1-3</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven inoperable stage IIIb-IV NSCLC

          -  ECOG PS 0-1

          -  Life expectancy &gt; 3 months

          -  Adequate blood functions: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet
             count ≥ 100 x 109/L, and hemoglobin ≥ 9 g / dL

          -  Adequate liver function: total bilirubin &lt;1.5 times the upper limit of normal (ULN);
             AST and ALT &lt;2.5 times ULN in patients without liver metastases, &lt;5 times ULN in
             patients with liver metastases

          -  Adequate renal function: serum creatinine ≤ 1.25 times ULN or calculated creatinine
             clearance ≥ 50 mL / min and urinary protein &lt;2+. In patients with baseline urinary
             protein ≥ 2+, 24 hours urine should be collected and 24 hours urine protein ≤ 1g

          -  International normalized ratio (INR) ≤ 1.5 and prothrombin time(PT) ≤ 1.5 times ULN
             within 7 days before enrollment

          -  Written informed consent

        Exclusion Criteria:

          -  Evidence of bleeding diathesis or coagulopathy

          -  History of hemoptysis, defined as bright red blood more than half a teaspoon 3 months
             before enrollment

          -  Previously received chemotherapy and radiotherapy and biological targeted therapy

          -  Uncontrolled hypertension (systolic blood pressure&gt; 150 mmHg and/or diastolic blood
             pressure&gt; 100 mm Hg)

          -  Clinically significant (ie, active) cardiovascular diseases, such as cerebrovascular
             accident (within 6 months before initiating treatment), myocardial infarction (within
             6 months before initiating treatment), unstable angina, congestive heart failure (New
             York Heart Association class ≥Grade II) , serious arrhythmia which needs medication
             during the study and may affect the study or can not be controlled by drugs

          -  Unhealed wounds, active peptic ulcer or fracture

          -  Gastrointestinal fistula, gastrointestinal perforation or intra-abdominal abscess
             within 6 months before enrollment

          -  Women with intact uterus (menopause more than two years excluded) who are unwilling to
             take effective non-hormonal contraception (IUD, spermicide barrier birth control
             device or sterilization) during the study. Male who are unwilling to take effective
             contraceptive measures during the study

          -  Participated in other clinical trials within 28 days before the initiation of
             treatment.

          -  Allergic to any of the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoliang Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming Fan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>September 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2012</study_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Fan Ming</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

